Shirin Khambata-Ford

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Responsiveness to cetuximab without mutations in EGFR
    Zenta Tsuchihashi
    N Engl J Med 353:208-9. 2005
  2. ncbi Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    Shirin Khambata-Ford
    Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    J Clin Oncol 25:3230-7. 2007
  3. ncbi Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
    Shirin Khambata-Ford
    Bristol Myers Squibb, 311 Pennington Rocky Hill Rd, 3B 2 06, Princeton, NJ 08543, USA
    J Clin Oncol 28:918-27. 2010
  4. ncbi Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer
    Fei Huang
    Bristol Myers Squibb Co, Route 206 and Province Line Rd, Room E1 293, Princeton, NJ 08453, USA
    Clin Cancer Res 18:1156-66. 2012
  5. ncbi Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Heinz-Josef Lenz
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    J Clin Oncol 24:4914-21. 2006
  6. ncbi K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
  7. ncbi Identification of promoter regions in the human genome by using a retroviral plasmid library-based functional reporter gene assay
    Shirin Khambata-Ford
    Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA
    Genome Res 13:1765-74. 2003

Detail Information

Publications7

  1. ncbi Responsiveness to cetuximab without mutations in EGFR
    Zenta Tsuchihashi
    N Engl J Med 353:208-9. 2005
  2. ncbi Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    Shirin Khambata-Ford
    Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    J Clin Oncol 25:3230-7. 2007
    ..This study was conducted to identify markers that are associated with disease control in patients treated with cetuximab...
  3. ncbi Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
    Shirin Khambata-Ford
    Bristol Myers Squibb, 311 Pennington Rocky Hill Rd, 3B 2 06, Princeton, NJ 08543, USA
    J Clin Oncol 28:918-27. 2010
    ..Additional exploratory analyses are essential to identify predictive markers and to optimize patient selection for cetuximab therapy in NSCLC...
  4. ncbi Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer
    Fei Huang
    Bristol Myers Squibb Co, Route 206 and Province Line Rd, Room E1 293, Princeton, NJ 08453, USA
    Clin Cancer Res 18:1156-66. 2012
    ....
  5. ncbi Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Heinz-Josef Lenz
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    J Clin Oncol 24:4914-21. 2006
    ..The severity of rash was related to efficacy. Neither EGFR kinase domain mutations nor EGFR gene amplification appear to be essential for response to cetuximab in this setting...
  6. ncbi K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
  7. ncbi Identification of promoter regions in the human genome by using a retroviral plasmid library-based functional reporter gene assay
    Shirin Khambata-Ford
    Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA
    Genome Res 13:1765-74. 2003
    ..This method promises to be a useful genome-wide function-based approach that can complement existing methods to look for promoters...